QIAGEN and Thermo Electron enter into Alliance.
Sep 22 2003

QIAGEN and Thermo Electron enter into Alliance.

VENLO, The Netherlands and Franklin, MA, September 22, 2003 - QIAGEN N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA), a leading provider of innovative products for nucleic acid separation, purification and handling and Thermo Electron Corporation, a world leader in high-tech instruments including liquid handling and microplate instrumentation technology have entered into an exclusive agreement to co-market and co-promote Thermo Electron's KingFisher® instrumentation technology together with QIAGEN's magnetic bead based nucleic acid separation and purification technology for use in nucleic acid-based applications in research and molecular diagnostics. Under the agreement, QIAGEN is granted a license to the KingFisher magnetic particle instrumentation technologies and will have the rights to market existing Kingfisher products. Thermo will actively and exclusively co-promote the QIAGEN nucleic acid purification consumables with their KingFisher instruments.

The KingFisher magnetic particle processing technology uses an advanced, patented technology based on magnetic rods moving particles through the processing steps in sample preparation processes of nucleic acids, proteins and cells. The technology has been implemented in instruments for low, medium and high throughputs. By combining the KingFisher instruments with the QIAGEN's proprietary magnetic bead technologies for nucleic acid separation and purification, the user has the ability to obtain automated, high-speed, high-quality, reproducible and efficient purification of nucleic acids.

"We are pleased to have found such an excellent partner for automated, magnetic bead based sample preparation as Thermo Electron Corporation," said Dr. Helge Lubenow, General Manager of QIAGEN AS. "KingFisher magnetic particle processing technology is highly synergistic to QIAGEN's BioRobot M class. The technology allows extremely easy process optimization of QIAGEN's proprietary magnetic bead technologies and can be incorporated in

current and future QIAGEN instrumentation as well as instrumentation purchased from Thermo Electron. The combination of Thermo Electron's Kingfisher technology with QIAGEN's magnetic particle technologies provides researchers with very attractive features in fully automated systems for sample preparation."

"We are very excited to be working with QIAGEN," explained Timo Hilden, acting President of Thermo Electron's Microplate Instrumentation Business. "QIAGEN is known for their expertise in developing and marketing solutions for purification applications. The combination of the Thermo KingFisher instruments and their chemistry is a wonderful opportunity to offer the user an integrated solution for purification applications."

About QIAGEN

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.

About Thermo Electron

A world leader in high-tech instruments, Thermo Electron Corporation helps life science, laboratory, and industrial customers advance scientific knowledge, enable drug discovery, improve manufacturing processes, and protect people and the environment with instruments, scientific equipment, and integrated software solutions. Based in Waltham, Massachusetts, Thermo Electron has revenues of more than $2 billion, and employs approximately 10,000 people in 30 countries worldwide. Further information on Thermo Electron can be found at http://www.thermo.com/. KingFisher is a registered trademark of Thermo Electron Corporation.


Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

Contacts:

Peer M. Schatz
Chief Financial Officer
QIAGEN N.V.
+49 2103 2911 702
e-mail: peer.schatz@QIAGEN.com

Dr. Solveigh Mähler
Manager Investor Relations
QIAGEN N.V.
+49 2103 2911 710
e-mail: solveigh.maehler@QIAGEN.com

Dr. Helge Lubenow
General Manager QIAGEN AS
QIAGEN AS
+47 23 00 5853
e-mail: helge.lubenow@QIAGEN.com

Lynda J. Thomas
Divisional Marketing Communications Manager
Thermo Electron Corporation
+1 508 541 0441
e-mail: lynda.thomas@thermo.com

 

SOCIAL SHARING

Share this page